SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-18-011549
Filing Date
2018-08-13
Accepted
2018-08-13 17:04:39
Documents
59
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 form10q.htm 10-Q 891258
2 image_001.jpg GRAPHIC 27991
3 ex31-1.htm EX-31.1 10708
4 ex32-1.htm EX-32.1 5516
  Complete submission text file 0001493152-18-011549.txt   3621502

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE endv-20180630.xml EX-101.INS 502702
6 XBRL SCHEMA FILE endv-20180630.xsd EX-101.SCH 41433
7 XBRL CALCULATION FILE endv-20180630_cal.xml EX-101.CAL 49078
8 XBRL DEFINITION FILE endv-20180630_def.xml EX-101.DEF 167611
9 XBRL LABEL FILE endv-20180630_lab.xml EX-101.LAB 305827
10 XBRL PRESENTATION FILE endv-20180630_pre.xml EX-101.PRE 247120
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

IRS No.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55453 | Film No.: 181013011
SIC: 2834 Pharmaceutical Preparations